BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations

BioLife Solutions (Nasdaq: BLFS) reported preliminary unaudited Q4 2025 revenue from continuing operations of $24.8M, up 20% from $20.7M in Q4 2024.

Rhea-AI Summary

BioLife Solutions (Nasdaq: BLFS) reported preliminary unaudited Q4 2025 revenue from continuing operations of $24.8M, up 20% from $20.7M in Q4 2024. Full-year 2025 preliminary unaudited revenue from continuing operations was $96.2M, up 29% from $74.6M in 2024 and slightly above the raised guidance high end of $96.0M (adjusted for the evo sale). Results exclude discontinued businesses and reflect a $1.3M biopreservation media shipment accelerated into Q3 at a customer's request. The company noted results are preliminary and unaudited and will finalize full 2025 financials when reporting complete results in February 2026.

Positive

• Full-year revenue +29% to $96.2M
• Q4 revenue +20% to $24.8M
• Revenue exceeded raised FY2025 guidance high end

Negative

• Preliminary unaudited results subject to final adjustments
• Approx. $1.3M of biopreservation revenue shifted from Q4 into Q3

Argus Jan 12 session

-3.30% close to close Open Argus

Details

News Market Reaction – BLFS

In the Jan 12 session, BLFS declined 3.30%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights solid top-line execution, with Q4 2025 revenue from continuing operatio...

Analysis

This announcement highlights solid top-line execution, with Q4 2025 revenue from continuing operations of $24.8M and full-year revenue of $96.2M, a 29% increase over 2024 that exceeds the company’s raised guidance range. The results follow divestitures of non-core businesses and a shift toward higher-value cell processing and biopreservation products. Investors may watch the finalized audited results, future 2026 guidance, and any updates on margin expansion and recurring revenue strength as management targets profitable growth.

Key Figures

Q4 2025 revenue (cont.): $24.8M Q4 YoY growth: 20% Q4 2024 revenue (cont.): $20.7M +5 more

Q4 2025 revenue (cont.)

$24.8M

Unaudited revenue from continuing operations, Q4 2025

Q4 YoY growth

20%

Increase vs. Q4 2024 revenue from continuing operations

Q4 2024 revenue (cont.)

$20.7M

Unaudited revenue from continuing operations, Q4 2024

FY 2025 revenue (cont.)

$96.2M

Preliminary unaudited full-year 2025 revenue from continuing operations

FY 2024 revenue (cont.)

$74.6M

Revenue from continuing operations, full year 2024

FY 2025 growth

29%

Increase in revenue from continuing operations vs. 2024

2025 guidance range

$95.0M–$96.0M

Previously raised FY 2025 revenue guidance (continuing ops, post-evo sale)

Pulled-forward revenue

$1.3M

Biopreservation media revenue shifted from Q4 2025 into Q3 2025

Historical Context

5 past events · Latest: Nov 20

5 events

1. Nov 20

   New facility launch

   24h Move

   -0.7%

   Opened Aby J. Mathew Center to showcase and develop biopreservation products.

2. Nov 17

   Investor conferences

   24h Move

   -0.3%

   Announced participation in several investor conferences and refreshed presentation.

3. Nov 06

   Quarterly earnings

   24h Move

   -2.0%

   Strong Q3 growth, higher guidance, and completion of evo cold chain sale.

4. Oct 23

   Earnings date notice

   24h Move

   +0.5%

   Scheduled Q3 2025 results release and conference call/webcast details.

5. Oct 07

   Asset divestiture

   24h Move

   -0.8%

   Announced sale of evo cold chain subsidiary to refocus on core CGT tools.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cell and gene therapy, cgT, biopreservation media, adjusted ebitda margin, +2 more

6 terms

cell and gene therapy medical

"cell processing tools and services for the cell and gene therapy ("CGT") market"

Therapies that use living cells or altered genes to treat or cure disease by repairing, replacing or reprogramming parts of the body; think of it as swapping or reprogramming malfunctioning hardware or software inside the body. Investors watch these treatments closely because they can command high prices and offer one-time or long-lasting benefits, but they also carry big development costs, complex manufacturing and regulatory risks that can cause large swings in a company’s value.

cgT medical

"cell processing tools and services for the cell and gene therapy ("CGT") market"

CGT stands for capital gains tax, a tax on the profit an investor realizes when selling an asset such as stocks, property, or funds. It matters because it reduces the money you actually keep from a sale—like having to share part of a prize—so investors consider tax rates, how long they hold an asset, and timing of sales to maximize after-tax returns.

biopreservation media medical

"does not include approximately $1.3 million in biopreservation media revenue"

Biopreservation media are specially formulated liquids used to keep cells, tissues or biological samples alive and stable during storage and transport, like a refrigerated packing solution that prevents damage and decay. For investors, the quality of these media matters because they influence product shelf life, success of lab tests, regulatory acceptance, and logistics costs for therapies and diagnostics—factors that affect revenue, margins and market adoption.

adjusted ebitda margin financial

"further expansion of adjusted EBITDA margin as we benefit from additional"

Adjusted EBITDA margin shows how much profit a company makes from its core operations, expressed as a percentage of its total revenue, after removing certain one-time or unusual expenses and income. It helps investors understand the company's true earning ability from regular business activities, making it easier to compare performance over time or with other companies. Think of it as measuring the efficiency of a business in turning sales into profits, excluding irregular adjustments.

u.s. generally accepted accounting principles financial

"full financial statements for the year ended December 31, 2025 prepared in accordance with U.S. generally accepted"

U.S. generally accepted accounting principles (U.S. GAAP) are the standard set of rules and conventions U.S. companies use to prepare their financial statements so numbers are reported consistently. For investors, GAAP is like a common recipe or rulebook that makes it possible to compare earnings, assets and liabilities across companies and trust that figures aren’t being presented in wildly different ways; differences in methods can materially affect perceived profitability and risk.

forward looking statements regulatory

"Certain statements contained in this press release are not historical facts and may be forward looking statements"

Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter

Full year unaudited revenue from continuing operations of $96.2 million exceeded the high end of the previously raised guidance range for FY2025

BOTHELL, Wash., Jan. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced preliminary fourth quarter and full year 2025 unaudited revenue from continuing operations.

Roderick de Greef, BioLife's Chairman and CEO, commented, "We closed out the year strong with 20% growth in fourth quarter revenue from continuing operations. For the year, revenue from continuing operations increased 29% on a like-for-like basis compared with 2024, largely driven by growth in our biopreservation product line. Following the divestiture of our evo product line in October, we are well positioned as a pure-play cell processing company focused on high-value, recurring revenue franchises. Our streamlined, market-leading product portfolio and strong financial position support our expectations for profitable growth and long-term value creation.

"Looking ahead to 2026, we expect revenue growth across our product portfolio along with further expansion of adjusted EBITDA margin as we benefit from additional operating leverage. We plan to provide 2026 financial guidance when reporting our complete 2025 results in February."

Fourth Quarter and Full Year 2025 Preliminary Unaudited Revenue from Continuing Operations

BioLife completed the divestitures of evo in 2025 and Global Cooling, Inc., SciSafe, Inc. and Custom Biogenic Systems in 2024, and is presenting the below results as discontinued operations for all periods presented. All amounts, percentages, and disclosures for all periods presented in this press release reflect only the continuing operations of the Company unless otherwise noted.

• Preliminary and unaudited revenue from continuing operations for the fourth quarter of 2025 was $24.8 million, an increase of 20% from $20.7 million for the fourth quarter of 2024. The revenue for the fourth quarter of 2025 does not include approximately $1.3 million in biopreservation media revenue that was initially scheduled for shipment in the fourth quarter of 2025 but was accelerated into the third quarter of 2025 at a commercial customer's request.
• Preliminary and unaudited revenue from continuing operations for 2025 was $96.2 million, an increase of 29% from $74.6 million for 2024. This exceeded the top end of the revenue guidance range that was raised in November 2025 to $95.0 million to $96.0 million, as adjusted for the sale of the evo business.

(As a result of presenting amounts in millions, rounding differences may exist in the percentages above.)

About BioLife Solutions

BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.

Preliminary Revenue Results

This press release includes estimated revenue results for the fourth quarter and fiscal year ended December 31, 2025, which are preliminary and unaudited and represent the most current information available to Company management, as financial closing procedures for the quarter and the fiscal year ended December 31, 2025 are not yet complete. The Company's actual results may differ from these preliminary results due to the ongoing completion of its financial closing procedures and final adjustments. These preliminary unaudited revenue results should not be viewed as a substitute for full financial statements for the year ended December 31, 2025 prepared in accordance with U.S. generally accepted accounting principles.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," "may," "estimate," "guidance," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Media & Investor Relations

At the Company

Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com

Investors

Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-announces-preliminary-fourth-quarter-and-full-year-2025-unaudited-revenue-from-continuing-operations-302658084.html

SOURCE BioLife Solutions, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were BioLife (BLFS) preliminary Q4 2025 revenues?

Preliminary unaudited Q4 2025 revenue from continuing operations was $24.8M.

How much revenue did BioLife (BLFS) report for full-year 2025?

Preliminary unaudited full-year 2025 revenue from continuing operations was $96.2M.

Did BioLife (BLFS) meet or exceed its FY2025 revenue guidance?

Yes. Preliminary revenue of $96.2M slightly exceeded the raised guidance high end of $96.0M (adjusted for evo sale).

Why might BioLife (BLFS) preliminary revenue change before the final report?

Results are preliminary and unaudited; final closing procedures and adjustments may change reported amounts.

How did shipment timing affect BioLife (BLFS) Q4 2025 revenue?

Approximately $1.3M of biopreservation media revenue was accelerated into Q3 at a customer's request, reducing Q4 reported revenue.